Side-by-side · Research reference
CartalaxvsDihexa
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-StrongHUMAN-REVIEWED7/28 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
01Mechanism of Action
Parameter
Cartalax
Dihexa
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
c-Met receptor (HGF receptor tyrosine kinase)
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Feedback intact?
—
—
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Dihexa
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
Not established — no human trials
Evidence basis
Animal mechanistic studies only
Pre-clinical / Rodent models
Animal studies
—
Mouse/rat models only — dosing not translatable to humans
Clinical status
—
No Phase 1, 2, or 3 trials published
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Dihexa
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
Dihexa
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
None available — no human clinical trials
Theoretical c-Met risks
—
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
Pre-clinical tolerability
—
Not systematically reported in available studies
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Dihexa
- ·Not approved for human use — research compound only
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
05Administration Protocol
Parameter
Cartalax
Dihexa
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
—